Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.56 |
| ▸ | RXFP4 | Q8TDU9 | 5/20 | 0.55 |
| ▸ | RXFP3 | Q9NSD7 | 5/20 | 0.55 |
| ▸ | MC4R | P32245 | 2/20 | 0.55 |
| ▸ | MC1R | Q01726 | 2/20 | 0.55 |
| ▸ | GLP1R | P43220 | 2/20 | 0.54 |
| ▸ | GCGR | P47871 | 2/20 | 0.54 |
| ▸ | MC3R | P41968 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.53 |
| ▸ | PRLHR | P49683 | 5/20 | 0.53 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.52 |
| ▸ | YAP1 | P46937 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462295 | 0.77 | MC4R (0.70) | F11MC4RMC1RMC3RRXFP1 | |
| SCHEMBL30152284 | 0.76 | PRLHR (0.63) | GLP1RGCGRPRLHR | |
| Cycloviolacin O2 SCHEMBL30497729 | 0.75 | KCNMA1 (0.62) | RXFP4RXFP3MC4RMC1RRXFP1 | |
| SCHEMBL30893931 | 0.75 | F12 (0.55) | MC4RMC1RMC3R | |
| SCHEMBL29467923 | 0.75 | MC4R (0.64) | F11MC4RMC1RMC3RRXFP1 | |
| SCHEMBL29387178 | 0.75 | INSR (0.59) | MC4RMC1RMC3RRXFP1INSR | |
| Vitri A SCHEMBL30132415 | 0.74 | KCNMA1 (0.64) | RXFP4RXFP3MC4RMC1RMC3R | |
| SCHEMBL29374066 | 0.74 | MC4R (0.53) | MC4RMC1RGLP1RGCGRMC3R | |
| SCHEMBL29904329 | 0.73 | F11 (0.58) | F11MC4RMC1RGLP1RGCGR | |
| SCHEMBL29353028 | 0.72 | F12 (0.57) | F11MC4RMC1RMC3RRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606937-B2 | Humanized antibodies with ultralong complementary determining regions | TAURUS BIOSCIENCES, LLC (US) | 2026-04-21 | — | — | US | disclosed |
| US-20230287598-A1 | HUMANIZED ANTIBODIES WITH ULTRALONG COMPLEMENTARY DETERMINING REGIONS | TAURUS BIOSCIENCES, LLC | 2023-09-14 | — | — | US | disclosed |
| US-11530493-B2 | Humanized antibodies with ultralong complementary determining regions | TAURUS BIOSCIENCES, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-11484576-B2 | Methods of promoting corticospinal neuronal outgrowth in neuronal lesions using a pro-regenerative human osteopontin fragment | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606937-B2 | Humanized antibodies with ultralong complementary determining regions | IGLV6-57, FCGR3B, VSIR | F11 420/4885RXFP4 380/4885RXFP3 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.